Insights
Search Results
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Alerts
6.26.26
FTC Conditions Aurobindo’s Acquisition of Lannett on Divestiture of Four Generic Drugs
On June 18, 2026, the Federal Trade Commission (FTC) announced that it would allow Aurobindo Pharma Limited’s approximately $250 million acquisition of Lannett Company, Inc. to proceed, subject to a proposed consent order requiring Aurobindo to divest four overlapping generic pharmaceutical products to Quagen Pharmaceuticals, LLC. The Commission voted 2-0 to issue an administrative complaint and accept the consent agreement for a 30-day public comment period.
Client Highlights
6.24.26
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
Client Highlights
6.23.26
Firm Advises QCi on Acquisition of NHanced
On June 22, 2026, Quantum Computing Inc. (QCi), an innovative, quantum optics and integrated photonics technology company, announced the completion of acquiring NHanced Semiconductors for a combination of cash and QCi stock valued at $73.1 million, subject to customary adjustments, and up to an additional $72.0 million if certain performance targets are achieved. Wilson Sonsini Goodrich & Rosati advised QCi on the transaction.
Client Highlights
6.22.26
Firm Advises Denali Therapeutics on Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
On June 18, 2026, Denali Therapeutics, a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform, announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million. Wilson Sonsini Goodrich & Rosati advised Denali on the transaction.
Client Highlights
6.05.26
Wilson Sonsini Advises SewerAI on Strategic Investment
On June 2, 2026, SewerAI, a leading AI platform for sewer and underground infrastructure intelligence, announced a major strategic investment led by JMI Equity, a leading growth equity software investor based in the greater Washington, D.C., area and San Diego, with continued participation from Innovius Capital, Epic Ventures, and Bentley Systems. Wilson Sonsini Goodrich & Rosati advised SewerAI on the transaction.
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
6.03.26
Wilson Sonsini Advises Asana on Acquisition of StackAI
On May 28, 2026, Asana, Inc., the operating system for human-agent teams, announced that it has completed the acquisition of StackAI, a no-code AI workflow platform that enables companies to design, test, deploy, and govern custom AI agents and intelligent automation of business-critical workflows. Wilson Sonsini Goodrich & Rosati advised Asana on the transaction.
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
Client Highlights
6.01.26
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Alerts
5.29.26
Insights from the 2026 FTC Workshop on Last-Minute Antitrust Remedy Proposals
On May 20, 2026, the Federal Trade Commission (FTC) hosted “Eleventh-Hour Antitrust Remedy Proposals and Litigating the Fix” Workshop, which provided meaningful insight into how the agency is likely to approach merger remedies under its current leadership. Chairman Andrew Ferguson delivered the opening remarks, and Commissioner Mark Meador gave the closing remarks.
Client Highlights
4.14.26
Wilson Sonsini Advises Special Committee of the Board in Globalstar's Acquisition by Amazon
On April 14, 2026, Amazon and Globalstar announced they have entered into a definitive merger agreement under which Amazon will acquire Globalstar, a leading mobile satellite services (MSS) operator, a pioneer in non-geostationary orbit (NGSO) satellites and D2D technology, and a provider of critical and emergency communications to customers around the world. Wilson Sonsini Goodrich & Rosati is representing the special committee of Globalstar’s board of directors on the transaction.